Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

138 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-02-29

Study Completion Date

2013-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a four-arm, randomized, controlled, clinical trial examining the efficacy of of cognitive behavioral therapy (CBT)-I and armodafinil in reducing insomnia in 226 female breast cancer patients who report sleep disturbances following completion of chemotherapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cognitive Behavioral Therapy With or Without Armodafinil in Treating Cancer Survivors With Insomnia and Fatigue After Chemotherapy

NCT01019187

Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED PHASE2

Management of Insomnia in Breast Cancer Patients

NCT01011218

Insomnia Fatigue

COMPLETED PHASE2

Treating Chronic Insomnia in Breast Cancer Patients

NCT00337272

Chronic Insomnia

TERMINATED PHASE4

Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression

NCT00518986

Sleep Disorders Obstructive Sleep Apnea Major Depressive Disorder +1 more

COMPLETED PHASE4

The Effects of Modafinil on Waking Function and on Sleep in Individuals With Primary Insomnia

NCT00124384

Primary Insomnia

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Treatment Protocol: CBT-I and armodafinil are being studied in a four-arm, randomized, controlled, clinical trial of 226 cancer survivors with chronic insomnia who are at least one month post treatment. The seven-week intervention is designed to determine the efficacy and acceptability of these treatment strategies in reducing insomnia in cancer survivors. Assessments will be made by questionnaires before, during, and two weeks following the study intervention. All ancillary treatments, as appropriate for control of symptoms caused by the cancer or its treatment may be administered as clinically indicated.

Withdrawal of Sleep Medications: All participants, prior to beginning the baseline data collection phase of the study, must have withdrawn from all sleep medications, including: prescription, over-the-counter, CAM and herbal remedies for at least one week prior to beginning the study.

CBT-I (Arms 3 \& 4): CBT-I will be provided on an individual basis to all patients in study Arms 3 \& 4 by a licensed clinical psychologist trained in CBT-I by Dr. Perlis. Subjects in these two study arms will receive 7 weeks of CBT-I, using a structured research grade protocol developed at the UR-SNRL. This manualized intervention, which exists as a published text: Perlis et al., 2005, includes four essential components: Sleep Restriction Therapy, Stimulus Control Instruction, Sleep Hygiene Guidelines, and a session of cognitive therapy.

Data Collection: Patients will complete the Insomnia Severity (ISI) at the time of consent and every Friday during weeks 3-11 of the study. A follow-up call by study personnel will be made to each participant not currently receiving CBT-I on each of these Fridays to promote compliance, prompt completion, assess potential side effects of study medication, and answer patient questions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Insomnia Fatigue Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1 - CBT-I + placebo

CBT-I and placebo

Group Type EXPERIMENTAL

Placebo Comparator

Intervention Type DRUG

Placebo for 47 days

CBT-I

Intervention Type BEHAVIORAL

Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)

2 - CBT-I + Armodafinil

CBT-I + Armodafinil

Group Type EXPERIMENTAL

armodafinil

Intervention Type DRUG

Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)

CBT-I

Intervention Type BEHAVIORAL

Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)

3 - Placebo only

Placebo only

Group Type PLACEBO_COMPARATOR

Placebo Comparator

Intervention Type DRUG

Placebo for 47 days

4 - Armodafinil only

Armodafinil only

Group Type EXPERIMENTAL

armodafinil

Intervention Type DRUG

Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

armodafinil

Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)

Intervention Type DRUG

Placebo Comparator

Placebo for 47 days

Intervention Type DRUG

CBT-I

Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Have a diagnosis of cancer.
2. Be able to understand written and spoken English
3. Be able to swallow medication
4. Have preferred sleep phase between 7:30 pm and 11:00 am
5. Be willing to discontinue any medications/OTCs/Herbals for sleep for the 11-week study period
6. Be presumed to be in a state of cancer remission; use of tamoxifen, an aromatase inhibitor, and/or Herceptin is permitted
7. Self-report problems with insomnia for at least three months and that the insomnia began or got worse with the onset of cancer or treatment
8. Have completed chemotherapy and or radiation not less than one month ago. Note: Both types of treatment must be completed at least one month ago if patient receives chemotherapy and radiation therapy and there is no outer limit to how long ago treatments were completed.)
9. Report insomnia on the SDS-CL at a frequency of at least 3 days a week

Exclusion Criteria

1. Have ever taken modafinil or had CBT-I therapy. CBT-I therapy for the sake of this protocol will be defined as any cognitive behavioral-based treatment for insomnia that includes a sleep restriction component.
2. Have an unstable medical or psychiatric illness (Axis I-current or within the last 5 years)
3. Have a history of seizures or severe headaches, or uncontrolled cardiac disease or hypertension
4. Be presently taking an anticoagulant or a corticosteroid
5. Have taken amphetamines (e.g., methylphenidate, pemoline \[Cylert®\] or similar psycho stimulants) within the past 30 days
6. Be currently pregnant or nursing
7. Have a history of substance abuse, or meet criteria for current alcohol abuse or dependence as assessed by a CAGE test score \>=2 or an Alcohol Use Disorders Identification Test (AUDIT) score \>=13
8. Have surgery planned within the study period
9. Have have ever been diagnosed with sleep apnea or have sleep apnea as indicated by endorsing either question 11 (I wake up choking or gasping for air) or question 12 (My bed partner has noticed that I seem to stop breathing) on the Sleep Disorders Symptom Check at the "Often" or "Frequently" level.

Minimum Eligible Age

21 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No